Chemists use electrochemistry to amp up drug manufacturing

Give your medicine a jolt. By using electrochemistry, future pharmaceuticals - including many of the top prescribed medications in the United States - soon may be easily scaled up to be manufactured in a more sustainable way. Currently, making pharmaceuticals involves creating complex organic molecules that require several chemical steps and intense energy. The process also spawns copious amounts of environmentally harmful - and usually toxic - waste.

At the heart of many popular pharmaceuticals are vicinal diamines, which contain carbon-nitrogen chemical bonds, a bioactive foundation for the medicine. According to Song Lin, assistant professor of chemistry, many widely consumed therapeutic agents have these diamines, including prescription-strength flu medicines, penicillin and some anti-cancer drugs.

Lin and his team have developed a technique that creates vicinal diamines more easily and without the toxic waste. The process uses electricity and chemistry - electrochemistry - and then employs Earth-abundant manganese.

"The current process generates a lot of waste product to make this chemical bond. When you can create a product electrosynthetically, rather than chemically, it is much more straightforward and sustainable," Lin said.

Fu N, Sauer GS, Saha A, Loo A, Lin S.
Metal-catalyzed electrochemical diazidation of alkenes.
Science. 2017 Aug 11;357(6351):575-579. doi: 10.1126/science.aan6206.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Syntropy to unlock the value of scientific data in…

Merck, a leading science and technology company, and software company Palantir Technologies, today announced their intent to form a joint venture under the brand name Syn...